Hillevax Inc
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical prod… Read more
Hillevax Inc (HLVX) - Total Assets
Latest total assets as of June 2025: $174.91 Million USD
Based on the latest financial reports, Hillevax Inc (HLVX) holds total assets worth $174.91 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hillevax Inc - Total Assets Trend (2019–2024)
This chart illustrates how Hillevax Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hillevax Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Hillevax Inc's total assets of $174.91 Million consist of 92.6% current assets and 7.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 80.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Hillevax Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hillevax Inc's current assets represent 92.6% of total assets in 2024, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 80.2% of total assets in 2024, down from 89.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Hillevax Inc Competitors by Total Assets
Key competitors of Hillevax Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Hillevax Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hillevax Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hillevax Inc is currently not profitable relative to its asset base.
Hillevax Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 26.39 | 5.14 | 0.15 |
| Quick Ratio | 26.39 | 5.14 | 0.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $156.09 Million | $ 203.36 Million | $ -2.77 Million |
Hillevax Inc - Advanced Valuation Insights
This section examines the relationship between Hillevax Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.71 |
| Latest Market Cap to Assets Ratio | 0.43 |
| Asset Growth Rate (YoY) | -44.1% |
| Total Assets | $192.69 Million |
| Market Capitalization | $83.07 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hillevax Inc's assets below their book value (0.43 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hillevax Inc's assets decreased by 44.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hillevax Inc (2019–2024)
The table below shows the annual total assets of Hillevax Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $192.69 Million | -44.06% |
| 2023-12-31 | $344.43 Million | +8.58% |
| 2022-12-31 | $317.21 Million | +149.46% |
| 2021-12-31 | $127.16 Million | +25080.00% |
| 2020-12-31 | $505.00K | +11.97% |
| 2019-12-31 | $451.00K | -- |